T7 Peptide (TFA)T7 Peptide (TFA) - High-quality laboratory reagent available from Gentaur. Catalog: 804-HY-P10323A-01.804-HY-P10323A-01804-HY-P10323A-01Business & Industrial > Science & LaboratoryT7 Peptide (TFA)
Gentaur
EUR12027-02-23

T7 Peptide (TFA)

CAT:
804-HY-P10323A-01
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
T7 Peptide (TFA) - image 1

T7 Peptide (TFA)

  • Description:

    T7 peptide (Tumstatin (74-98), human) TFA is an endothelial cell-specific inhibitor. T7 peptide TFA interacts with αVβ3 integrin to inhibit the FAK, PI3-kinase, PKB/Akt, and mTOR signaling pathways in endothelial cells, ultimately suppressing protein synthesis and inducing apoptosis[1].
  • Product Name Alternative:

    Tumstatin (74-98), human (TFA)
  • UNSPSC:

    12352209
  • Target:

    Apoptosis; FAK; Integrin; mTOR
  • Related Pathways:

    Apoptosis; Cytoskeleton; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
  • Field of Research:

    Cancer
  • Purity:

    98.41
  • Smiles:

    O=C([C@@H](N)[C@@H](C)O)N[C@H](C(N1[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]2C(C)C)=O)CC(O)=O)=O)CC(N)=O)=O)C(C)C)=O)CC(N)=O)=O)CSSC[C@H](NC2=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC(C)C)=O)CC3=CNC4=CC=CC=C34)=O)CC5=CC=C(O)C=C5)=O)CO)=O)CC6=CC=C(O)C=C6)=O)CC(O)=O)=O)CC(N)=O)=O)CCCNC(N)=N)=O)CO)=O)C)=O)CC7=CC=CC=C7)=O)CC(N)=O)=O)=O)CC8=CC=CC=C8)=O)CC(C)C)=O)CC9=CC=CC=C9)=O)CCC1)=O)CCSC.O=C(O)C(F)(F)F.[x]
  • Molecular Formula:

    C137H189N33O39S3.xC2HF3O2
  • Molecular Weight:

    3018.36 (free base)
  • References & Citations:

    [1]Maeshima Y, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 2002 Jan 4;295 (5552) :140-3.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
  • Scientific Category:

    Peptides
  • Clinical Information:

    No Development Reported